IPO Timeline
Broker Results (T-2)
2021-12-08
Some brokers release in afternoon
Grey Market (T-1)
2021-12-09
Afternoon
HKEX Allotment (T-1)
2021-12-09
Evening
Registrar Allotment (T-1)
2021-12-09
Evening
Listing Day (T)
2021-12-10
First day of trading
Company Overview
| Stock Name | 北海康成製藥有限公司 - B |
|---|---|
| Stock Code | 01228 |
| Company Full Name | 北海康成製藥有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事研究、開發及商業化生物科技療法，并專注於罕見疾病。 |
| Listing Date | 2021-12-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區容創路17號時代凌宇大廈3樓301室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.canbridgepharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.18 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 68.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 68,524,680 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 8.9 |
|---|---|
| First Day Open | HK$ 9.8 |
| First Day Change | -26.93% |
| First Day Volume | 29094800.0 |
| First Day Turnover | 266971000.0 |
Use of Proceeds
| Use of Proceeds | 1、約45.4%或274.2 百萬港元將分配用于為我們的核心產品候選藥物CAN008的現有及日后研發、CMC開發以及生產流程發展提供資金； 2、約24.0%或145.0百萬港元將分配用于為以下我們產品管線中的主要產品及候選產品提供資金； 3、約1.8%或10.9百萬港元將分配用于我們產品管線中其他產品及候選產品的現有及日后研發提供資金； 4、約12.0%或72.5百萬港元，預計用于為CAN201、CAN202及其他基因治療候選藥物的現有及日后研發提供資金； 5、16.8%或101.5百萬港元將分配用于為研發及其他一般業務用途提供資金。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
Overall Coordinators (3)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
海通国际证券有限公司 CE AAF806
Joint Bookrunners (5)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
海通国际证券有限公司 CE AAF806
招商证券（香港）有限公司 CE AAI650
中银国际亚洲有限公司 CE AET863
Joint Lead Managers (6)
摩根士丹利亚洲有限公司 CE AAD291
富瑞金融集团香港有限公司 CE ATS546
海通国际证券有限公司 CE AAF806
招商证券（香港）有限公司 CE AAI650
中银国际亚洲有限公司 CE AET863
富途证券国际（香港）有限公司 CE AZT137
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Belinda A. Termeer | 15,578,220 HKD | — | 2.27% | — | 6 months | 2022-06-10 |
| 2 | General Atlantic Singapore CP Pte. Ltd. | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
| 3 | Hudson Bay Master Fund LTD | 62,312,880 HKD | — | 9.09% | — | 6 months | 2022-06-10 |
| 4 | Janus Henderson Funds | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
| 5 | RA Capital Healthcare Fund, L.P. | 233,685,480 HKD | — | 34.11% | — | 6 months | 2022-06-10 |
| 6 | 江苏瑞华投资控股集团有限公司 | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
| 7 | 药明生物产业基金 | 38,939,460 HKD | — | 5.68% | — | 6 months | 2022-06-10 |
Directors & Management
| Chairman | 薛群 |
|---|---|
| Company Secretary | 馬倩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | RA Capital Management L.P.(14.2%);薛群(9.85%);無錫藥明康德新藥開發股份有限公司(9.51%);Qiming Corporate GP IV, Ltd(7.74%) |
|---|
IPO Timeline
